Evidence map›Paper›PMID 41070100›Full record

ArticleJHEP reports : innovation in hepatology2025

Isolation and immortalization of human portal vein endothelial cells: A novel research tool for studying splanchnic vasculature.

Aina Anton, Sarah Shalaby, Júlia Campalans, Annabel Blasi, Yiliam Fundora, Rosa Montañés, Héctor García-Calderó, Lixin Sun, Joana Codina, Josepmaria Argemí and 4 more

Abstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Aina AntonBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Sarah ShalabyBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Júlia CampalansBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Annabel BlasiBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Yiliam FundoraDepartment of Surgery, Division of Hepatobiliary and General Surgery, Institut de Malalties Digestives I Metabòliques (IMDiM), Hospital Clínic, Barcelona, Spain.
Rosa MontañésBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Héctor García-CalderóBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Lixin SunChina Pharmaceutical University, State key laboratory of natural medicines, New Drug Screening and Pharmacodynamics Evaluation Center, Nanjing, China.
Joana CodinaBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Josepmaria ArgemíCIBEREHD (Centro de Investigación Biomèdica en Red Enfermedades Hepáticas y Digestivas), AGAUR SGR2021 01115 Madrid, Spain.
Olga Tura-CeideTranslational Research Group on Cardiovascular Respiratory Diseases (CAREs), Dr. Josep Trueta University Hospital de Girona, Santa Caterina Hospital de Salt and Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), Parc Hospitalari Martí i Julià, Salt, Spain.
Joan Carles García-PagánBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Genís CampreciósBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Virginia Hernández-GeaBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Cirrhosis profoundly impacts extrahepatic vasculature, particularly altering the portal venous system, leading to increased portal pressure, portosystemic collaterals, and portal vein thrombosis, which heightens morbidity and reduces survival in liver disease. Although intrahepatic vascular changes in cirrhosis are well studied, molecular insights into extrahepatic alterations in the splanchnic region remain limited owing to the inaccessibility of the human portal vein and suboptimal preclinical models. Here, we aim to isolate, characterize, and immortalize primary human portal vein endothelial cells (PVECs) to enhance understanding of pathophysiological changes during liver disease and establish a platform for future drug testing. Methods: PVECs (n = 12) and inferior cava vein (ICV, n = 9) endothelial cells (ECs) were isolated from human portal vein or ICV, obtained during hepatic transplantation, using trypsinization, mechanical scratching, and FACS. EC identity was confirmed through characterization of gene and protein marker expression as well as functional assays assessing angiogenic capacity (tube formation), migratory ability (wound closure), and acetylated low-density lipoprotein uptake. PVECs were immortalized (iPVECs) with lentiviral particles expressing the SV40 large T-antigen. Results: Isolated PVECs confirmed classical endothelial morphology and functionality, expressing hallmark proteins and functions. PVECs exhibited a distinct transcriptomic profile from ICVEC and systemic ECs, enriched in pathways for vascular remodeling and stress response. iPVECs retained endothelial identity and preserved the PVEC-specific transcriptomic traits across more than 20 passages. Conclusions: We successfully isolated, characterized, and immortalized PVECs, creating a novel tool to study splanchnic vascular diseases. These cells retain transcriptomic uniqueness distinct from systemic venous ECs, enabling investigation of vascular dysfunction mechanisms in liver disease and supporting translational research. Impact and implications: Portal hypertension and vascular complications are major drivers of morbidity in cirrhosis, yet extrahepatic vascular mechanisms remain poorly understood due to limited access to human portal vein tissue and inadequate models. By isolating, characterizing, and immortalizing primary human portal vein endothelial cells, we establish the first renewable, disease-relevant platform for studying splanchnic vascular biology. These immortalized portal vein endothelial cells preserve endothelial identity and transcriptomic signatures distinct from systemic venous cells, providing unique insights into vascular remodeling and stress responses in liver disease. This resource enables mechanistic discovery and drug testing aimed at improving outcomes in portal hypertension and related complications.

Indexed as

CirrhosisSplanchnic systemVascular dysfunctionVascular endothelium

Identifiers

PMID41070100
PMCPMC12506482

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.